For: | Leung C, Yeoh SW, Patrick D, Ket S, Marion K, Gow P, Angus PW. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015; 21(4): 1189-1196 [PMID: PMC4306163 DOI: 10.3748/wjg.v21.i4.1189] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i4/1189.htm |
Number | Citing Articles |
1 |
N. Golse, A. El Bouyousfi, F. Marques, B. Bancel, K. Mohkam, C. Ducerf, P. Merle, M. Sebagh, D. Castaing, A. Sa Cunha, R. Adam, D. Cherqui, E. Vibert, J.-Y. Mabrut. Large hepatocellular carcinoma: Does fibrosis really impact prognosis after resection?. Journal of Visceral Surgery 2018; 155(4): 265 doi: 10.1016/j.jviscsurg.2017.10.015
|
2 |
Jingjing Cai, Xiao‐Jing Zhang, Hongliang Li. The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis. Hepatology 2019; 70(3): 1026 doi: 10.1002/hep.30506
|
3 |
Jesús Rivera-Esteban, Sergio Muñoz-Martínez, Mónica Higuera, Elena Sena, María Bermúdez-Ramos, Juan Bañares, María Martínez-Gomez, M. Serra Cusidó, Alba Jiménez-Masip, Sven M. Francque, Frank Tacke, Beatriz Minguez, Juan M. Pericàs. Phenotypes of Metabolic Dysfunction–Associated Steatotic Liver Disease–Associated Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology 2024; 22(9): 1774 doi: 10.1016/j.cgh.2024.03.028
|
4 |
Yi Dong, Wen-Ping Wang, Won Jae Lee, Maria Franca Meloni, Dirk-Andre Clevert, Maria Cristina Chammas, Andrea Tannapfel, Antonella Forgione, Fabio Piscaglia, Christoph Frank Dietrich. Hepatocellular carcinoma in the non-cirrhotic liver. Clinical Hemorheology and Microcirculation 2022; 80(4): 423 doi: 10.3233/CH-211309
|
5 |
|
6 |
Ziwei Li, Dongyu Duan, Li Li, Dan Peng, Yue Ming, Rui Ni, Yao Liu. Tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress. Frontiers in Pharmacology 2024; 15 doi: 10.3389/fphar.2024.1382256
|
7 |
Stefano Bellentani, Gianluca Svegliati Baroni, Fabio Piscaglia, Claudio Tiribelli. Natural history of nonalcoholic steatohepatitis–associated hepatocellular carcinoma. Clinical Liver Disease 2016; 8(4): 105 doi: 10.1002/cld.582
|
8 |
Luis Calzadilla Bertot, Leon A Adams. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2019; 13(2): 179 doi: 10.1080/17474124.2019.1549989
|
9 |
Masao Omata, Ann-Lii Cheng, Norihiro Kokudo, Masatoshi Kudo, Jeong Min Lee, Jidong Jia, Ryosuke Tateishi, Kwang-Hyub Han, Yoghesh K. Chawla, Shuichiro Shiina, Wasim Jafri, Diana Alcantara Payawal, Takamasa Ohki, Sadahisa Ogasawara, Pei-Jer Chen, Cosmas Rinaldi A. Lesmana, Laurentius A. Lesmana, Rino A. Gani, Shuntaro Obi, A. Kadir Dokmeci, Shiv Kumar Sarin. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International 2017; 11(4): 317 doi: 10.1007/s12072-017-9799-9
|
10 |
Margarita N. German, Megan K. Lutz, Perry J. Pickhardt, Richard J. Bruce, Adnan Said. Statin Use is Protective Against Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2020; 54(8): 733 doi: 10.1097/MCG.0000000000001260
|
11 |
Talya L. Dayton, Vasilena Gocheva, Kathryn M. Miller, William J. Israelsen, Arjun Bhutkar, Clary B. Clish, Shawn M. Davidson, Alba Luengo, Roderick T. Bronson, Tyler Jacks, Matthew G. Vander Heiden. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma. Genes & Development 2016; 30(9): 1020 doi: 10.1101/gad.278549.116
|
12 |
Aakash Desai, Sonia Sandhu, Jin-Ping Lai, Dalbir Singh Sandhu. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World Journal of Hepatology 2019; 11(1): 1-18 doi: 10.4254/wjh.v11.i1.1
|
13 |
Mingyue Song, Yuhao Tao, Hanjun Zhang, Mingzhan Du, Lingchuan Guo, Chunhong Hu, Weiguo Zhang. Gd-EOB-DTPA-enhanced MR imaging features of hepatocellular carcinoma in non-cirrhotic liver. Magnetic Resonance Imaging 2024; 114: 110241 doi: 10.1016/j.mri.2024.110241
|
14 |
进玲 刘. Serological Biomarkers Related to
Non-Cirrhotic Hepatocellular
Carcinoma: Promising
Applications in Clinical
Diagnosis and Prognosis. Advances in Clinical Medicine 2025; 15(02): 142 doi: 10.12677/acm.2025.152327
|
15 |
Luis Calzadilla Bertot, Leon Adams. The Natural Course of Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences 2016; 17(5): 774 doi: 10.3390/ijms17050774
|
16 |
Marta Romero-Gutiéttez, María Abadanes Tercero, Juan Ruiz Martín, Juan Diego Castro Limo, Tomás Artaza Varasa, Concepción González de Frutos, Gema de la Cruz Pérez, Juan José Sánchez Ruano, Ana Zaida Gómez Moreno, Rafael Gómez Rodríguez. Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver.. Revista Española de Enfermedades Digestivas 2019; 111 doi: 10.17235/reed.2019.6180/2018
|
17 |
Lorenzo A. Orci, Marco Sanduzzi-Zamparelli, Berta Caballol, Victor Sapena, Nicola Colucci, Ferran Torres, Jordi Bruix, María Reig, Christian Toso. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. Clinical Gastroenterology and Hepatology 2022; 20(2): 283 doi: 10.1016/j.cgh.2021.05.002
|
18 |
Marcus J. Lyall, John P. Thomson, Jessy Cartier, Raffaele Ottaviano, Timothy J. Kendall, Richard R. Meehan, Amanda J. Drake. Non-alcoholic fatty liver disease (NAFLD) is associated with dynamic changes in DNA hydroxymethylation. Epigenetics 2020; 15(1-2): 61 doi: 10.1080/15592294.2019.1649527
|
19 |
Marcus J. Lyall, Jessy Cartier, James A Richards, Diego Cobice, John P Thomson, Richard R Meehan, Stephen M Anderton, Amanda J Drake. Methyl donor deficient diets cause distinct alterations in lipid metabolism but are poorly representative of human NAFLD. Wellcome Open Research 2017; 2: 67 doi: 10.12688/wellcomeopenres.12199.1
|
20 |
Bjarki Sigurdsson, Ragna Sigurdardottir, Margret B. Arnardottir, Sigrun H. Lund, Jon G. Jonasson, Einar S. Björnsson. A nationwide study on hepatocellular carcinoma. Cancer Epidemiology 2020; 69: 101835 doi: 10.1016/j.canep.2020.101835
|
21 |
Makiko Taniai, Etsuko Hashimoto, Maki Tobari, Kazuhisa Kodama, Katsutoshi Tokushige, Masakazu Yamamoto, Tadatoshi Takayama, Masahiko Sugitani, Keiji Sano, Fukuo Kondo, Toshio Fukusato. Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: A multicenter study using immunohistochemical analysis of adenoma‐related markers. Hepatology Research 2018; 48(12): 947 doi: 10.1111/hepr.13203
|
22 |
Patrick S Harris, Ross M Hansen, Meagan E Gray, Omar I Massoud, Brendan M McGuire, Mohamed G Shoreibah. Hepatocellular carcinoma surveillance: An evidence-based approach. World Journal of Gastroenterology 2019; 25(13): 1550-1559 doi: 10.3748/wjg.v25.i13.1550
|
23 |
Thai P Hong, Paul J Gow, Michael Fink, Anouk Dev, Stuart K Roberts, Amanda Nicoll, John S Lubel, Ian Kronborg, Niranjan Arachchi, Marno Ryan, William W Kemp, Virginia Knight, Vijaya Sundararajan, Paul Desmond, Alexander JV Thompson, Sally J Bell. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population‐based study. Medical Journal of Australia 2018; 209(8): 348 doi: 10.5694/mja18.00373
|
24 |
Xuan-vinh Kevin Nguyen, Jason Zhang, Ken Lee Chin, Stephen Bloom, Amanda J. Nicoll. Is Hepatocellular Carcinoma in Fatty Liver Different to Non-Fatty Liver?. Nutrients 2022; 14(18): 3875 doi: 10.3390/nu14183875
|
25 |
Jose Tadeu Stefano, Fernanda de Mello Malta, Priscila Brizola de Campos, Pedro Fernandes Andrade, Denise Cerqueira Paranaguá-Vezzozo, Flair Jose Carrilho, Claudia P. Oliveira. NAFLD and NASH. 2020; : 191 doi: 10.1007/978-3-030-37173-9_11
|
26 |
Pierre Bedossa, Valérie Paradis. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set. 2017; : 1272 doi: 10.1016/B978-0-323-34062-5.00089-3
|
27 |
Lampros Chrysavgis, Ilias Giannakodimos, Panagiota Diamantopoulou, Evangelos Cholongitas. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World Journal of Gastroenterology 2022; 28(3): 310-331 doi: 10.3748/wjg.v28.i3.310
|
28 |
Ahmet Uygun. Is That Possible to Stop or Cease the NASH to Turn into HCC?. Journal of Gastrointestinal Cancer 2017; 48(3): 250 doi: 10.1007/s12029-017-9961-6
|
29 |
Partha Pal, Rajan Palui, Sayantan Ray. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World Journal of Hepatology 2021; 13(11): 1584-1610 doi: 10.4254/wjh.v13.i11.1584
|
30 |
Guozhen Cui, Robert C. Martin, Hang Jin, Xingkai Liu, Harshul Pandit, Hengjun Zhao, Lu Cai, Ping Zhang, Wei Li, Yan Li. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. Journal of Experimental & Clinical Cancer Research 2018; 37(1) doi: 10.1186/s13046-018-0781-8
|
31 |
Samer Gawrieh, Lara Dakhoul, Ethan Miller, Andrew Scanga, Andrew deLemos, Carla Kettler, Heather Burney, Hao Liu, Hamzah Abu‐Sbeih, Naga Chalasani, Julia Wattacheril. Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. Alimentary Pharmacology & Therapeutics 2019; 50(7): 809 doi: 10.1111/apt.15464
|
32 |
Cristina Margini, Jean F. Dufour. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver International 2016; 36(3): 317 doi: 10.1111/liv.13031
|
33 |
Zelin Tian, Chen Xu, Peijun Yang, Zhibin Lin, Wenlong Wu, Wenjie Zhang, Jian Ding, Rui Ding, Xuan Zhang, Kefeng Dou. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Frontiers in Immunology 2022; 13 doi: 10.3389/fimmu.2022.984728
|
34 |
Yuanliang Xie, Hongfeng Zhang, Chaoling Jin, Xiang Wang, Xiaoqi Wang, Jingting Chen, Yikai Xu. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits. Magnetic Resonance Imaging 2018; 48: 34 doi: 10.1016/j.mri.2017.12.017
|
35 |
Bubu A. Banini, Arun J. Sanyal. Mechanisms and Therapy of Liver Cancer. Advances in Cancer Research 2021; 149: 143 doi: 10.1016/bs.acr.2020.11.001
|
36 |
Jingjing Cai, Xiao‐Jing Zhang, Hongliang Li. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Medicinal Research Reviews 2019; 39(1): 328 doi: 10.1002/med.21515
|
37 |
Javier Martinez-Useros, Jesus Garcia-Foncillas. Obesity and colorectal cancer: molecular features of adipose tissue. Journal of Translational Medicine 2016; 14(1) doi: 10.1186/s12967-016-0772-5
|
38 |
Jorge A. Marrero, Laura M. Kulik, Claude B. Sirlin, Andrew X. Zhu, Richard S. Finn, Michael M. Abecassis, Lewis R. Roberts, Julie K. Heimbach. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68(2): 723 doi: 10.1002/hep.29913
|
39 |
Anisha Jain, Benjamin Mazer, Yanhong Deng, Maria Ciarleglio, Dhanpat Jain, Tamar Taddei, Xuchen Zhang. Hepatocellular Carcinoma. American Journal of Clinical Pathology 2022; 157(2): 305 doi: 10.1093/ajcp/aqab125
|
40 |
Vincent Chiu, Christine Yee, Nathan Main, Igor Stevanovski, Matthew Watt, Trevor Wilson, Peter Angus, Tara Roberts, Nicholas Shackel, Chandana Herath. Oncogenic plasmid DNA and liver injury agent dictates liver cancer development in a mouse model. Clinical Science 2024; 138(19): 1227 doi: 10.1042/CS20240560
|
41 |
Andrea Marengo, Chiara Rosso, Elisabetta Bugianesi. Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis. Annual Review of Medicine 2016; 67(1): 103 doi: 10.1146/annurev-med-090514-013832
|
42 |
Jessica Howell, Amit Samani, Binish Mannan, Saur Hajiev, Leila Motedayen Aval, Rebecca Abdelmalak, Vincent C. Tam, Dominik Bettinger, Robert Thimme, Tamar H. Taddei, David E. Kaplan, Max Seidensticker, Rohini Sharma. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: an international cohort study. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221100106
|
43 |
Benedetta Donati, Paola Dongiovanni, Stefano Romeo, Marica Meroni, Misti McCain, Luca Miele, Salvatore Petta, Silvia Maier, Chiara Rosso, Laura De Luca, Ester Vanni, Stefania Grimaudo, Renato Romagnoli, Fabio Colli, Flaminia Ferri, Rosellina Margherita Mancina, Paula Iruzubieta, Antonio Craxi, Anna Ludovica Fracanzani, Antonio Grieco, Stefano Ginanni Corradini, Alessio Aghemo, Massimo Colombo, Giorgio Soardo, Elisabetta Bugianesi, Helen Reeves, Quentin M. Anstee, Silvia Fargion, Luca Valenti. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals. Scientific Reports 2017; 7(1) doi: 10.1038/s41598-017-04991-0
|
44 |
Bashar Mohamad, Vaishal Shah, Mykola Onyshchenko, Mohammed Elshamy, Federico Aucejo, Rocio Lopez, Ibrahim A. Hanouneh, Razan Alhaddad, Naim Alkhouri. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis. Hepatology International 2016; 10(4): 632 doi: 10.1007/s12072-015-9679-0
|
45 |
Umut Aykutlu, Asuman Argon, Mehmet Orman, Sezgin Ulukaya, Murat Zeytunlu, Zeki Karasu, Fulya Günşar, Deniz Nart, Ulus Akarca, Funda Yilmaz. Steatotic and Steatohepatitic Hepatocellular Carcinomas. American Journal of Surgical Pathology 2021; 45(9): 1252 doi: 10.1097/PAS.0000000000001714
|
46 |
Cristiane Valle Tovo, Angelo Zambam de Mattos, Gabriela Perdomo Coral, Giovana D P Sartori, Livia Villela Nogueira, Gustavo Tovo Both, Cristiane A Villela-Nogueira, Angelo A de Mattos. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis. World Journal of Gastroenterology 2023; 29(2): 343-356 doi: 10.3748/wjg.v29.i2.343
|
47 |
Annalisa Cespiati, Felice Cinque, Marica Meroni, Rosa Lombardi, Paola Dongiovanni, Anna Ludovica Fracanzani. An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians. Biomedicines 2023; 11(2): 586 doi: 10.3390/biomedicines11020586
|
48 |
Heinz Zoller, Herbert Tilg. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism 2016; 65(8): 1151 doi: 10.1016/j.metabol.2016.01.010
|
49 |
Dzeina Mezale, Ilze Strumfa, Andrejs Vanags, Matiss Mezals, Ilze Fridrihsone, Boriss Strumfs, Dainis Balodis. Liver Cirrhosis - Update and Current Challenges. 2017; doi: 10.5772/intechopen.68771
|
50 |
Marcus J. Lyall, Jessy Cartier, John P. Thomson, Kate Cameron, Jose Meseguer-Ripolles, Eoghan O'Duibhir, Dagmara Szkolnicka, Baltasar Lucendo Villarin, Yu Wang, Giovanny Rodriguez Blanco, Warwick B. Dunn, Richard R. Meehan, David C. Hay, Amanda J. Drake. Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells. Philosophical Transactions of the Royal Society B: Biological Sciences 2018; 373(1750): 20170362 doi: 10.1098/rstb.2017.0362
|
51 |
|
52 |
Yoshio Sumida, Masashi Yoneda, Yuya Seko, Hiroshi Ishiba, Tasuku Hara, Hidenori Toyoda, Satoshi Yasuda, Takashi Kumada, Hideki Hayashi, Takashi Kobayashi, Kento Imajo, Masato Yoneda, Toshifumi Tada, Takumi Kawaguchi, Yuichiro Eguchi, Satoshi Oeda, Hirokazu Takahashi, Eiichi Tomita, Takeshi Okanoue, Atsushi Nakajima. Surveillance of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Diagnostics 2020; 10(8): 579 doi: 10.3390/diagnostics10080579
|
53 |
Kanokwan Pinyopornpanish, Wael Al-Yaman, Srinivasan Dasarathy, Carlos Romero-Marrero, Arthur McCullough. Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival. Digestive Diseases and Sciences 2022; 67(6): 2677 doi: 10.1007/s10620-021-07048-5
|
54 |
Yoshitaka Sakurai, Naoto Kubota, Toshimasa Yamauchi, Takashi Kadowaki. Role of Insulin Resistance in MAFLD. International Journal of Molecular Sciences 2021; 22(8): 4156 doi: 10.3390/ijms22084156
|
55 |
Zobair M. Younossi, Linda Henry. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Reports 2021; 3(4): 100305 doi: 10.1016/j.jhepr.2021.100305
|
56 |
Emine Turkmen Samdanci. Hepatocellular Carcinoma - Challenges and Opportunities of a Multidisciplinary Approach. 2022; doi: 10.5772/intechopen.99842
|
57 |
Xinyue Lin, Juanhong Zhang, Yajun Chu, Qiuying Nie, Junmin Zhang. Berberine prevents NAFLD and HCC by modulating metabolic disorders. Pharmacology & Therapeutics 2024; 254: 108593 doi: 10.1016/j.pharmthera.2024.108593
|
58 |
Monika Vyas, Dhanpat Jain. A practical diagnostic approach to hepatic masses. Indian Journal of Pathology and Microbiology 2018; 61(1): 2 doi: 10.4103/IJPM.IJPM_578_17
|
59 |
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison. NAFLD‐related hepatocellular carcinoma: The growing challenge. Hepatology 2023; 77(1): 323 doi: 10.1002/hep.32542
|
60 |
Maddalena Parafati, Sang Hyo Bae, R. Jason Kirby, Martina Fitzek, Preeti Iyer, Ola Engkvist, David M. Smith, Siobhan Malany. Pluripotent Stem Cell-Derived Hepatocytes Phenotypic Screening Reveals Small Molecules Targeting the CDK2/4-C/EBPα/DGAT2 Pathway Preventing ER-Stress Induced Lipid Accumulation. International Journal of Molecular Sciences 2020; 21(24): 9557 doi: 10.3390/ijms21249557
|
61 |
Matthew M. Yeh, Yajuan Liu, Michael Torbenson. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Human Pathology 2015; 46(11): 1769 doi: 10.1016/j.humpath.2015.07.018
|
62 |
Muhammad Imran Ahmad, Muhammad Umair Khan, Sudha Kodali, Akshay Shetty, S Michelle Bell, David Victor. Hepatocellular Carcinoma Due to Nonalcoholic Fatty Liver Disease: Current Concepts and Future Challenges. Journal of Hepatocellular Carcinoma 2022; : 477 doi: 10.2147/JHC.S344559
|
63 |
Francesco Izzo, Meredith C. Mason, Eric J. Silberfein, Nader N. Massarweh, Cary Hsu, Hop S. Tran Cao, Raffaele Palaia, Mauro Piccirillo, Andrea Belli, Renato Patrone, Roberta Fusco, Vincenza Granata, Steven A. Curley. Long-Term Survival and Curative-Intent Treatment in Hepatitis B or C Virus-Associated Hepatocellular Carcinoma Patients Diagnosed during Screening. Biology 2022; 11(11): 1597 doi: 10.3390/biology11111597
|
64 |
Maria Reig, Martina Gambato, Nancy Kwan Man, John P. Roberts, David Victor, Lorenzo A. Orci, Christian Toso. Should Patients With NAFLD/NASH Be Surveyed for HCC?. Transplantation 2019; 103(1): 39 doi: 10.1097/TP.0000000000002361
|
65 |
Amir Sultan, Chimaobi M. Anugwom, Zerihun Wondifraw, Grace A. Braimoh, Abate Bane, Jose D. Debes. Single center analysis of therapy and outcomes of hepatocellular carcinoma in Sub-Saharan Africa. Expert Review of Gastroenterology & Hepatology 2020; 14(10): 1007 doi: 10.1080/17474124.2020.1802246
|
66 |
N. Golse, A. El Bouyousfi, F. Marques, B. Bancel, K. Mohkam, C. Ducerf, P. Merle, M. Sebagh, D. Castaing, A. Sa Cunha, R. Adam, D. Cherqui, E. Vibert, J.-Y. Mabrut. Volumineux carcinome hépatocellulaire : quel est l’impact de la fibrose sur le pronostic après résection ?. Journal de Chirurgie Viscérale 2018; 155(4): 267 doi: 10.1016/j.jchirv.2017.09.005
|
67 |
Marie Boyle, Quentin M. Anstee. Evidence‐based Gastroenterology and Hepatology 4e. 2019; : 523 doi: 10.1002/9781119211419.ch35
|
68 |
Florian Koutny, Elmar Aigner, Christian Datz, Sophie Gensluckner, Andreas Maieron, Andrea Mega, Bernhard Iglseder, Patrick Langthaler, Vanessa Frey, Bernhard Paulweber, Eugen Trinka, Bernhard Wernly. Relationships between education and non-alcoholic fatty liver disease. European Journal of Internal Medicine 2023; 118: 98 doi: 10.1016/j.ejim.2023.07.039
|
69 |
Stephanie Klein, Jean-François Dufour. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Hepatic Oncology 2017; 4(3): 83 doi: 10.2217/hep-2017-0013
|
70 |
Marie Boyle, Quentin M. Anstee. Editorial: hepatocellular carcinoma in non‐cirrhotic NASH—a troubling reality. Alimentary Pharmacology & Therapeutics 2018; 48(9): 1021 doi: 10.1111/apt.14982
|
71 |
Erin M. Sadler, Neil Mehta, Mamatha Bhat, Anand Ghanekar, Paul D. Greig, David R. Grant, Francis Yao, Gonzalo Sapisochin. Liver Transplantation for NASH-Related Hepatocellular Carcinoma Versus Non-NASH Etiologies of Hepatocellular Carcinoma. Transplantation 2018; 102(4): 640 doi: 10.1097/TP.0000000000002043
|
72 |
Harshul Pandit, Yan Li, Qianqian Zheng, Wei Guo, Youxi Yu, Suping Li, Robert C.G. Martin. Carcinogenetic initiation contributed by EpCAM+ cancer cells in orthotopic HCC models of immunocompetent and athymic mice. Oncotarget 2020; 11(22): 2047 doi: 10.18632/oncotarget.27454
|
73 |
Shiv Chitturi, Vincent Wai‐Sun Wong, Wah‐Kheong Chan, Grace Lai‐Hung Wong, Simon Kin‐Hung Wong, Jose Sollano, Yen‐Hsuan Ni, Chun‐Jen Liu, Yu‐Cheng Lin, Laurentius Adrianto Lesmana, Seung Up Kim, Etsuko Hashimoto, Masahide Hamaguchi, Khean‐Lee Goh, Jiangao Fan, Ajay Duseja, Yock Young Dan, Yogesh Chawla, Geoff Farrell, Henry Lik‐Yuen Chan. The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups. Journal of Gastroenterology and Hepatology 2018; 33(1): 86 doi: 10.1111/jgh.13856
|
74 |
Sui‐Weng Wong, Yi‐Wen Ting, Wah‐Kheong Chan. Epidemiology of non‐alcoholic fatty liver disease‐related hepatocellular carcinoma and its implications. JGH Open 2018; 2(5): 235 doi: 10.1002/jgh3.12070
|
75 |
Daria A. Teplyuk, Aliya A. Kaisina, Shabnam I. Ibragimova, Afina A. Bestavashvili, Irina O. Tinkova, Evgeniia Iu. Pashkova, Jamilya A. Kaibullayeva, Alexander V. Nersesov, Chavdar S. Pavlov. Non-alcoholic fatty liver disease: from understanding risk factors to finding optimal treatment regimens: A review. Consilium Medicum 2023; 25(5): 325 doi: 10.26442/20751753.2023.5.202272
|
76 |
Rupie Jamwal, Venkatram Krishnan, Dinesh Singh Kushwaha, Rajat Khurana. Hepatocellular carcinoma in non-cirrhotic versus cirrhotic liver: a clinico-radiological comparative analysis. Abdominal Radiology 2020; 45(8): 2378 doi: 10.1007/s00261-020-02561-z
|
77 |
Nikolaos-Andreas T. Anastasopoulos, Georgios D. Lianos, Vera Tatsi, Anastasia Karampa, Anna Goussia, Georgios K. Glantzounis. Clinical heterogeneity in patients with non-alcoholic fatty liver disease-associated hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2020; 14(11): 1025 doi: 10.1080/17474124.2020.1802244
|
78 |
Masamichi Hayashi, Suguru Yamada, Hiroshi Tanabe, Hideki Takami, Yoshikuni Inokawa, Fuminori Sonohara, Dai Shimizu, Norifumi Hattori, Mitsuro Kanda, Chie Tanaka, Goro Nakayama, Masahiko Koike, Michitaka Fujiwara, Yasuhiro Kodera. High Serum Uric Acid Levels Could Be a Risk Factor of Hepatocellular Carcinoma Recurrences. Nutrition and Cancer 2021; 73(6): 996 doi: 10.1080/01635581.2020.1779758
|
79 |
Marco Castellana, Rossella Donghia, Luisa Lampignano, Fabio Castellana, Roberta Zupo, Rodolfo Sardone, Giovanni De Pergola, Gianluigi Giannelli. Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. Journal of Clinical Medicine 2021; 10(20): 4638 doi: 10.3390/jcm10204638
|
80 |
Jialu Yang, Huimin Xu, Yijun Zhao, Pengju Sun, Yuanyuan Li, Ting Chen, Yanmei Zhou. Bivariate tracking of NIR phototherapeutic probe that illuminates the deterioration process of NAFLD-HCC. Biosensors and Bioelectronics 2025; 269: 116967 doi: 10.1016/j.bios.2024.116967
|
81 |
Chuanzheng Sun, Xunyang Liu, Zhongjie Yi, Xuefei Xiao, Mingshi Yang, Gui Hu, Huaizheng Liu, Liangkan Liao, Feizhou Huang. Genome‐wide analysis of long noncoding RNA expression profiles in patients with non‐alcoholic fatty liver disease. IUBMB Life 2015; 67(11): 847 doi: 10.1002/iub.1442
|
82 |
Sarah Da Won Bae, Jacob George, Liang Qiao. From MAFLD to hepatocellular carcinoma and everything in between. Chinese Medical Journal 2022; 135(5): 547 doi: 10.1097/CM9.0000000000002089
|
83 |
Subrat K. Acharya, Sawan Bopanna. Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different?. Journal of Clinical and Experimental Hepatology 2020; 10(5): 518 doi: 10.1016/j.jceh.2020.04.004
|
84 |
Andrea Marengo, Ramy Ibrahim Kamal Jouness, Elisabetta Bugianesi. Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults. Clinics in Liver Disease 2016; 20(2): 313 doi: 10.1016/j.cld.2015.10.010
|
85 |
Noah J. Daniels, Courtney E. Hershberger, Matthew Kerosky, Chase J. Wehrle, Roma Raj, Nihal Aykun, Daniela S. Allende, Federico N. Aucejo, Daniel M. Rotroff. Biomarker Discovery in Liver Disease Using Untargeted Metabolomics in Plasma and Saliva. International Journal of Molecular Sciences 2024; 25(18): 10144 doi: 10.3390/ijms251810144
|
86 |
Ekta Dhamija, Shashi Bala Paul, Saurabh Kedia. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma. Indian Journal of Medical Research 2019; 149(1): 9 doi: 10.4103/ijmr.IJMR_1456_17
|
87 |
Hae‐Ki Min, Hitoshi Maruyama, Byoung Kuk Jang, Masahiko Shimada, Faridoddin Mirshahi, Shunlin Ren, Youngman Oh, Puneet Puri, Arun J. Sanyal. Suppression of IGF binding protein‐3 by palmitate promotes hepatic inflammatory responses. The FASEB Journal 2016; 30(12): 4071 doi: 10.1096/fj.201600427R
|
88 |
Feizhou Huang, Huaizheng Liu, Zhao Lei, Zhenzhou Li, Tianyi Zhang, Mingshi Yang, Kefu Zhou, Chuanzheng Sun. Long noncoding RNA CCAT1 inhibits miR‐613 to promote nonalcoholic fatty liver disease via increasing LXRα transcription. Journal of Cellular Physiology 2020; 235(12): 9819 doi: 10.1002/jcp.29795
|
89 |
Chee-Kiat Tan. Peretinoin as an adjuvant therapy for hepatocellular carcinoma. Expert Review of Gastroenterology & Hepatology 2016; 10(11): 1201 doi: 10.1080/17474124.2016.1238303
|
90 |
Jongbeom Shin, Jung Hwan Yu, Young-Joo Jin, Jin-Woo Lee. Incidence and Clinical Features of Hepatitis C Virus-associated Hepatocellular Carcinoma Patients without Liver Cirrhosis in Hepatitis B Virus-endemic Area. Journal of Liver Cancer 2021; 21(1): 34 doi: 10.17998/jlc.21.1.34
|
91 |
Claudia D. Fuchs, Michael Trauner. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nature Reviews Gastroenterology & Hepatology 2022; 19(7): 432 doi: 10.1038/s41575-021-00566-7
|
92 |
Jian Wu. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Oncotarget 2106; 7(27): 42762 doi: 10.18632/oncotarget.8641
|